XBiotech Inc

XBIT

Company Profile

  • Business description

    XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

  • Contact

    5217 Winnebago Lane
    AustinTX78744
    USA

    T: +1 512 386-2900

    E: [email protected]

    http://www.xbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    87

Stocks News & Analysis

stocks

ASX biotech expands diagnostics portfolio after FDA approval

FDA nod adds another growth driver for ASX share.
stocks

Is it time to bail on Australian stocks?

Is your home bias costing your portfolio better returns?
stocks

ASX share undervalued despite margin woes

Short term margin pressure yet shares remain undervalued on improved outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,874.5025.200.28%
CAC 408,140.0649.780.62%
DAX 4025,497.8595.570.38%
Dow JONES (US)52,093.11328.09-0.63%
FTSE 10010,727.0868.950.65%
HKSE24,713.7846.540.19%
NASDAQ25,981.57204.84-0.78%
Nikkei 22563,923.00438.900.69%
NZX 50 Index13,622.72138.501.03%
S&P 5007,585.730.000.00%
S&P/ASX 2008,696.5024.000.28%
SSE Composite Index3,891.6027.320.71%

Market Movers